{'52WeekChange': 2.551181,
 'SandP52WeekChange': None,
 'address1': '2631 Hanover Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 45.12,
 'askSize': 800,
 'averageDailyVolume10Day': 251375,
 'averageVolume': 311831,
 'averageVolume10days': 251375,
 'beta': None,
 'beta3Year': None,
 'bid': 42.9,
 'bidSize': 3000,
 'bookValue': 7.397,
 'category': None,
 'circulatingSupply': None,
 'city': 'Palo Alto',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 45.96,
 'dayLow': 42.97,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -23.955,
 'enterpriseToRevenue': None,
 'enterpriseValue': 1579235712,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 55.003716,
 'fiftyTwoWeekHigh': 82.75,
 'fiftyTwoWeekLow': 9.47,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 19898669,
 'forwardEps': -4.43,
 'forwardPE': -10.1693,
 'fromCurrency': None,
 'fullTimeEmployees': 41,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.20673999,
 'heldPercentInstitutions': 0.84181,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/kodiak.com',
 'longBusinessSummary': 'Kodiak Sciences Inc., a clinical stage '
                        'biopharmaceutical company, provides novel '
                        "therapeutics to treat retinal diseases. The company's "
                        'lead product candidate is KSI-301, a vascular '
                        'endothelial growth factor (VEGF)-biological agent '
                        'that is in Phase 1b clinical study to treat wet '
                        'age-related macular degeneration (AMD) and diabetic '
                        'retinopathy. Its preclinical stage product candidate '
                        'include KSI-501, a bispecific anti-interleukin 6/VEGF '
                        'bioconjugate to target inflammation and abnormal '
                        'angiogenesis in the pathogenesis of retinal vascular '
                        "diseases. The company's early research pipeline "
                        'include KSI-601, a triplet inhibitor for dry AMD. The '
                        'company was formerly known as Oligasis, LLC and '
                        'changed its name to Kodiak Sciences Inc. in September '
                        '2015. Kodiak Sciences Inc. was founded in 2009 and is '
                        'headquartered in Palo Alto, California.',
 'longName': 'Kodiak Sciences Inc.',
 'market': 'us_market',
 'marketCap': 2004026752,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_321992085',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -63773000,
 'nextFiscalYearEnd': 1640908800,
 'open': 45.15,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -1.25,
 'phone': '650-281-0850',
 'previousClose': 45.1,
 'priceHint': 2,
 'priceToBook': 6.0903068,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 45.96,
 'regularMarketDayLow': 42.97,
 'regularMarketOpen': 45.15,
 'regularMarketPreviousClose': 45.1,
 'regularMarketPrice': 45.15,
 'regularMarketVolume': 247283,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 44452700,
 'sharesPercentSharesOut': 0.109799996,
 'sharesShort': 4885330,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4125249,
 'shortName': 'Kodiak Sciences Inc',
 'shortPercentOfFloat': 0.2042,
 'shortRatio': 14.22,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'KOD',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.604,
 'twoHundredDayAverage': 56.902016,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '557800df-7007-3d0a-a42a-afe9fdcb28bd',
 'volume': 247283,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://kodiak.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94304'}